Casey IRACs are produced by an AI that analyzes the opinion’s content to construct its analysis. While we strive for accuracy, the output may not be flawless. For a complete and precise understanding, please refer to the linked opinions above.

Keywords

appealtrialpatent

patent

Related Cases

Amgen Inc. v. Sanofi, 598 U.S. 594, 143 S.Ct. 1243, 215 L.Ed.2d 537, 23 Cal. Daily Op. Serv. 4369, 2023 Daily Journal D.A.R. 4541, 29 Fla. L. Weekly Fed. S 794

Facts

Amgen developed a PCSK9-inhibiting drug and obtained patents for antibodies that bind to PCSK9 and block it from degrading LDL receptors. In 2014, Amgen obtained additional patents claiming a broader genus of antibodies, which included potentially millions of undisclosed antibodies. Sanofi, a competitor, argued that Amgen's patents were invalid for lack of enablement, asserting that Amgen had not provided sufficient guidance for a person skilled in the art to make and use all the claimed antibodies. The district court and Federal Circuit sided with Sanofi, leading to Amgen's appeal.

After Amgen obtained the 2014 patents, it sued Sanofi for infringement. Sanofi replied that it was not liable to Amgen for infringement because Amgen's relevant claims were invalid under the Patent Act's 'enablement' requirement.

Issue

Did Amgen's patent specification enable a person skilled in the art to make and use the entire class of antibodies claimed, particularly those with unknown amino acid sequences?

Rule

Under the Patent Act, a patent applicant must describe the invention in full, clear, concise, and exact terms to enable any person skilled in the art to make and use the invention, as mandated by 35 U.S.C. § 112(a).

That provision requires a patent applicant to describe the invention 'in such full, clear, concise, and exact terms as to enable any person skilled in the art … to make and use the [invention].' 35 U.S.C. § 112(a).

Analysis

The court analyzed whether Amgen's specification provided adequate guidance for making and using the entire class of antibodies claimed. It concluded that Amgen's claims were overly broad compared to the 26 specific antibodies it had described. The methods proposed by Amgen for generating additional antibodies were deemed insufficient, as they amounted to trial-and-error processes rather than providing clear enablement. The court found that Amgen had not enabled the broader class of antibodies it sought to claim.

Turning to the patent claims at issue in this case, Amgen's claims sweep much broader than the 26 exemplary antibodies it identifies by their amino acid sequences. Amgen has failed to enable all that it has claimed, even allowing for a reasonable degree of experimentation.

Conclusion

The Supreme Court affirmed the lower court's decision, holding that Amgen's specification did not enable the entire class of antibodies claimed, particularly those with unknown amino acid sequences.

Held: The courts below correctly concluded that Amgen failed 'to enable any person skilled in the art … to make and use the [invention]' as defined by the relevant claims.

Who won?

Sanofi prevailed in the case because the court found that Amgen's patent claims were not enabled as required by the Patent Act, failing to provide sufficient guidance for making and using the claimed antibodies.

You must be

Log In to Casey

Sign Up to Casey

Reset Your Password

Keywords

Related Cases

Cannon v. Dunn, 145 Ariz. 115, 700 P.2d 502

Sexton v. Sewell, 351 Ga.App. 273, 830 S.E.2d 605

United States v. Hendrickson, 949 F.3d 95, 72 V.I. 1172

Fisher v. Lowe, 122 Mich.App. 418, 333 N.W.2d 67

Kim v. Dean, 133 Wash.App. 338, 135 P.3d 978, 24 IER Cases 1347